FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA

Nti, Akosua A.; Serrano, Leona W.; Sandhu, Harpal S.; Uyhazi, Katherine E.; Edelstein, Ilaina D.; Zhou, Elaine J.; Bowman, Scott; Song, Delu; Gangadhar, Tara C.; Schuchter, Lynn M.; Mitnick, Sheryl; Huang, Alexander; Nichols, Charles W.; Amaravadi, Ravi K.; Kim, Benjamin J.; Aleman, Tomas S.

doi:10.1097/iae.0000000000002027

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA

Purpose: To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma. Methods: Patients with stage IV metastatic melanoma and BRAF V600E mutations (n = 11, 31–68 years of age)…